FDA Approves Moderna’s mRNA Flu Vaccine for Adults 50 and Older
The Food and Drug Administration (FDA) has approved Moderna's new mRNA-based flu vaccine, mFlusiva, for adults aged 50 and older. This marks the first flu vaccine to utilize the same mRNA technology used in COVID-19 vaccines. The new vaccine is…
Miami Fort Lauderdale, FL, August 6, 2026 —
The U.S. Food and Drug Administration (FDA) has granted approval for Moderna’s new influenza vaccine, mFlusiva. This marks a significant development as it is the first flu vaccine to employ mRNA technology, the same platform utilized in the widely distributed COVID-19 vaccines.
The newly approved vaccine, mFlusiva, is indicated for use in adults aged 50 years and older. This age group is often considered at higher risk for complications from influenza.
Moderna’s approach leverages messenger RNA (mRNA) technology to prompt the immune system to recognize and fight off influenza viruses. This is a departure from traditional flu vaccines, which typically use inactivated or weakened virus strains.
The availability of mFlusiva is anticipated soon. The company has stated that the vaccine will be accessible at select retail locations, though specific rollout dates and further details on distribution channels were not immediately provided.
This approval represents a new frontier in influenza prevention, potentially offering an alternative or complementary option to existing flu vaccines for a substantial segment of the population.
Story summarized from the original created by Kevin Boulandier on wsvn.com, see more information here.
Media gallery
